

Academic Industry Partnership (AIP): Managing the relationship

John W. Wong, Ph.D. Johns Hopkins University

Disclosure

JOHNS HOPKINS

- Supported in parts by
 - R01 CA158100; AIP with Xstrahl
 - R01 CA 161613; AIP with Elekta-Resonant
 - Maryland Biotech for Raven (QA system)
 - Research Agreements: Elekta, Xstrahl, JPLC, Toshiba Informatics
- Royalty
 - Elekta for Cone beam CT; Active Breathing Coordinator
 - Xstrahl for Small Animal Radiation Research
- Founder of JPLC Associates --- a QA device company

Academia: Clinical Needs & Medical Physics





Industry:		JOHNS HOPKINS
Clinical Needs	& Commercial	Products









Academic Industrial Partnership (AIP): ▲ PAR 10-169 → PAR 13-169

- Academic and industrial research partnerships to accelerate the translation of preclinical or clinical in vivo imaging systems and/or methods to solve a targeted cancer problem --- NCI only.
- · An inter-disciplinary, multi-institutional research team.
- · Support clinical trials.
- Will not support commercial production, or basic research.
- Innovation: coherent translation plan with in-field validation of near commercial quality systems/methods

AIP: A successful translation program

- The pioneering PAR 07-214 funded 37 grants funded: 19 products marketed; 20 clinical trials; 1 CE Mark approval; 24 FDA marketing and investigational approvals; and 79 instances of IP protection.
- 97/542 submissions funded through 2015; results not analyzed for the 27 PAR 10-169 and 20 PAR 13-169 grants
- The AIP procedure is a transformative methodology that provides a new standard for reliable delivery of new capabilities to end users.

JOHNS HOPKINS

Academic and Industrial Collaboration

- Have a clear sense of what and who are we working for – Academia → discovery (grants);
 - Industry \rightarrow successful commercial product
 - Both are necessary to benefit the patient
- The clinic is the laboratory to solve real problems that is available to the industry through academia
- · Partnership is not a contract
 - · deliverable (of what) is an uncomfortable term;
 - · beta testing is a different agreement

JOHNS HOPKINS

How to adapt to changes in the relationship

- Have clear expectation of the collaboration
 - IP, personal gain, etc
 - First right to refusal,... etc
- Hurdles; Sunshine Act, COI, etc.
- Cannot dictate the direction of the individual partners
- Industry is looking for knowledge, know-how and profitability
- Don't get mad if industry chooses a different path
- · Academia should look for clinical impact

JOHNS HOPKINS

Secure or renew funding with the industry

- · Believe in the impact and vision and stay the course
- Stay ahead to solve the clinical problem at hands
 A successful clinical solution will likely garner
- industrial support

 The Academia Industrial Partnership is a great
- mechanism
- provides funding to jump-start a project
- attain the innovation and translation goals of the NCI, the academia and the industry

The Cone-Beam CT story

Dual Beam Imaging, R01 CA66074, Pre-AIP mechanism
 — The limit of setup accuracy using MV and kV imaging



Dual Beam Imaging on Philips SL: 1996



- Not on a product roadmap
- Collaborate with Elekta (then Philips --- Kevin Brown) to mount a kV x-ray source to the drum gantry
- Hire a Philips engineer as consultant







- facilitated a 41cm x 41cm flat panel imager from EG&G
- worked out the performance of the
- Elekta-Synergy

The First Synergy Prototype: Christie 2001





- Synergy consortium (CBCT built on site): - Beaumont, Princess Margaret, Christie and NKI
- · Clinical workflow developed on site.



Synergy Product Launch: 2004



Conclusions: Academic Industrial Partnership

- It must be a win-win arrangement
 Not necessarily a financial gain for academia
- The common goal is to improve healthcare
- Academia is to pursue impact/transformation
- Industry is to produce the next successful and superior product to improve healthcare
- If you are lucky, you may get both !!!